BeyondSpring (BYSI) Total Current Liabilities (2015 - 2026)
BeyondSpring (BYSI) posted Total Current Liabilities of $12.4 million for Q1 2026, down 8.88% sequentially from $13.6 million in Q4 2025, and down 2.33% YoY from $12.7 million in Q1 2025.
BeyondSpring (BYSI) Total Current Liabilities (2015 - 2026) Analysis & Trends
BeyondSpring has reported Total Current Liabilities for 12 years, with the latest figure at $12.4 million in Q1 2026.
- Quarterly Total Current Liabilities fell 2.33% year-over-year to $12.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.4 million (down 2.33% YoY) and the FY2025 annual result came in at $13.6 million, up 23.31% from the prior year.
- Total Current Liabilities retreated to $12.4 million in Q1 2026 per BYSI's latest filing, from $13.6 million in the prior quarter.
- Over five years, Total Current Liabilities peaked at $13.6 million in Q4 2025 and troughed at $6.8 million in Q2 2023.
- A 5-year average of $10.5 million and a median of $11.1 million in 2022 frame the typical range for Total Current Liabilities.
- The sharpest annual moves came in 2022 and 2025: Total Current Liabilities tumbled 51.49% in 2022, then jumped 43.28% in 2025.
- Over 5 years, Total Current Liabilities stood at $7.4 million in 2022, then increased by 8.24% to $8.0 million in 2023, then jumped by 38.35% to $11.0 million in 2024, then climbed by 23.31% to $13.6 million in 2025, then slipped by 8.88% to $12.4 million in 2026.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $12.4 million, $13.6 million, and $12.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.51 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 438.74 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 630.93 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 2.49 Bn |
| 10 | BeyondSpring | 30.22 Mn | 30.22 Mn | - | 14.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.19 Mn |
| Mar 31, 2026 | 12.37 Mn |
| Dec 31, 2025 | 13.58 Mn |
| Sep 30, 2025 | 12.89 Mn |
| Jun 30, 2025 | 11.73 Mn |
| Mar 31, 2025 | 12.67 Mn |
| Dec 31, 2024 | 11.01 Mn |
| Jun 30, 2024 | 8.19 Mn |
| Dec 31, 2023 | 7.96 Mn |
| Jun 30, 2023 | 6.82 Mn |
| Dec 31, 2022 | 7.35 Mn |
| Jun 30, 2022 | 11.11 Mn |
| Dec 31, 2021 | 15.16 Mn |
| Sep 30, 2021 | 18.56 Mn |
| Jun 30, 2021 | 16.57 Mn |
| Mar 31, 2021 | 12.63 Mn |
| Dec 31, 2020 | 13.77 Mn |
| Sep 30, 2020 | 12.82 Mn |
| Jun 30, 2020 | 11.31 Mn |
| Mar 31, 2020 | 12.21 Mn |